Effectiveness and Safety of Radium-223 Dichloride

Meer over het boek

The book discusses the modification of the licensed indication for Radium-223 dichloride, an alpha particle-emitting radiopharmaceutical used in treating castration-resistant prostate cancer with bone metastases. Following the emergence of drug-drug interactions with commonly used medications like abiraterone and prednisone, its use has been limited to monotherapy or in combination with luteinizing hormone-releasing hormone analogues. This change has positioned Ra-223 as a third-line treatment, raising concerns regarding its effectiveness and safety in this new treatment context.